Regenerative medicine combines the latest advances in stem cell biology, embryology, tissue engineering and medicine to develop products for the replacement, restoration or regeneration of damaged or diseased cells and tissues. Tools used in regenerative medicine include biomaterials and extracellular matrices, lab-generated cells and tissues, and new biological molecules. These powerful technologies and tools are allowing clinical scientists to engineer and provide healthy cells, tissues and organs to patients with chronic degenerative diseases. This revolution in medical science changes the focus from treating symptoms of chronic and degenerative diseases to providing cures, and directly addresses costs that constitute approximately 83% of the 2.5 trillion dollar annual healthcare budget in the U.S. and are growing due to an aging population.
BioTime is led by Michael West, PhD., who pioneered the regenerative medicine industry. He founded Geron Corporation in the early 90’s which funded the first studies of cultured hESC to realize their potential to cure intractable human degenerative diseases. Dr. West has since built BioTime around key technologies and intellectual property that constitute major pillars of regenerative medicine.